Gilead Sciences Reports Financial Results for First Quarter 2025
Gilead Sciences Reports Financial Results for First Quarter 2025 Gilead Sciences, Inc. (Nasdaq: GILD) has unveiled its financial and operational performance for the first quarter of 2025, underscoring a steady…
Creyon Bio Names Industry Veteran Serge Messerlian as CEO to Drive Growth and Partnerships
Creyon Bio Names Industry Veteran Serge Messerlian as CEO to Drive Growth and Partnerships Creyon Bio, a biotechnology company pioneering the use of artificial intelligence in oligonucleotide therapy development, has…
Novocure’s Optune Lua Earns CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer
Novocure’s Optune Lua® Earns CE Mark Approval for Treating Metastatic Non-Small Cell Lung Cancer In a significant development for the treatment of advanced lung cancer, Novocure announced that its innovative…
Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025
Novocure to Present Late-Breaking Phase 3 PANOVA-3 Data for TTFields in Pancreatic Cancer at ASCO 2025 Novocure, a global leader in innovative cancer treatments, has announced that it will present…
Zai Lab to Present Phase 1 Data on DLL3-Targeted ADC ZL-1310 at ASCO 2025
Zai Lab to Present Phase 1 Data on DLL3-Targeted ADC ZL-1310 at ASCO 2025 Zai Lab Limited , a leading innovative biopharmaceutical company, announced today that it will present updated…
Pfizer Champions a New Era in Personalized Cancer Care at ASCO 2025 Annual Meeting
Pfizer Champions a New Era in Personalized Cancer Care at ASCO 2025 Annual Meeting Pfizer Inc. (NYSE: PFE), a global leader in biopharmaceutical innovation, announced its robust presence at the…
Verastem Gets U.S. IND Clearance for KRAS G12D Inhibitor VS-7375, Paving Way for Phase 1/2a Trial in Solid Tumors
Verastem Gets U.S. IND Clearance for KRAS G12D Inhibitor VS-7375, Paving Way for Phase 1/2a Trial in Solid Tumors Verastem Oncology (Nasdaq: VSTM), a Boston-based biopharmaceutical company at the forefront…
CN Bio and Pharmaron Forge Long-Term Global Partnership for OOC Tech Development
CN Bio and Pharmaron Forge Long-Term Global Partnership for OOC Tech Development In a significant stride toward revolutionizing preclinical drug development, CN Bio, a leading innovator in Organ-on-a-Chip (OOC) technologies,…
Halda Therapeutics Names Dr. Eyal Attar as New Chief Medical Officer
Halda Therapeutics Names Dr. Eyal Attar as New Chief Medical Officer Halda Therapeutics, a clinical-stage biotechnology company pioneering a new class of cancer therapeutics, has announced the appointment of Dr.…
FDA Grants Breakthrough Status to BrainChild Bio’s CAR T Therapy for Pediatric Brain Tumors
FDA Grants Breakthrough Status to BrainChild Bio’s CAR T Therapy for Pediatric Brain Tumors BrainChild Bio, Inc., a clinical-stage biotechnology company at the forefront of neuro-oncology cell therapy innovation, has…
EditCo Bio and Promega Team Up to Advance Cell-Based Research
EditCo Bio and Promega Team Up to Advance Cell-Based Research In a pivotal move set to reshape the landscape of functional genomics and cell engineering, EditCo Bio, Inc. has announced…
TNF Pharmaceuticals and Renova Health Harness AI to Fast-Track Drug Discovery
TNF Pharmaceuticals and Renova Health Harness AI to Fast-Track Drug Discovery In a significant advancement for data-driven drug development, TNF Pharmaceuticals has announced a strategic collaboration with Renova Health to…